n-(2-aminoethyl)-5-isoquinolinesulfonamide has been researched along with Disease Models, Animal in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
Kernig, K; Kirschstein, T; Köhling, R; Rohde, M; Würdemann, T | 1 |
2 other study(ies) available for n-(2-aminoethyl)-5-isoquinolinesulfonamide and Disease Models, Animal
Article | Year |
---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
The afterhyperpolarizing potential following a train of action potentials is suppressed in an acute epilepsy model in the rat Cornu Ammonis 1 area.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; CA1 Region, Hippocampal; Disease Models, Animal; Drug Interactions; Electric Stimulation; Enzyme Inhibitors; Epilepsy; Excitatory Amino Acid Antagonists; GABA Antagonists; In Vitro Techniques; Isoquinolines; Male; Neural Inhibition; Neurons; Pyridazines; Rats; Rats, Wistar; Statistics, Nonparametric; Sulfonamides; Time Factors | 2012 |